Anavex Life Sciences
AVXL
150 hedge funds and large institutions have $249M invested in Anavex Life Sciences in 2022 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 46 increasing their positions, 33 reducing their positions, and 14 closing their positions.
93% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 14
39% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 33
8% more funds holding
Funds holding: 139 → 150 (+11)
0.71% less ownership
Funds ownership: 32.89% → 32.18% (-0.71%)
20% less capital invested
Capital invested by funds: $310M → $249M (-$60.5M)
27% less call options, than puts
Call options by funds: $14.4M | Put options by funds: $19.7M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$4.46M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$3.58M |
| 3 |
Renaissance Technologies
New York
|
+$3.39M |
| 4 |
Millennium Management
New York
|
+$2.47M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$1.44M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$10.3M |
| 2 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$2.6M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.58M |
| 4 |
Rafferty Asset Management
New York
|
-$1.9M |
| 5 |
AWA
Aaron Wealth Advisors
Chicago,
Illinois
|
-$1.75M |
AVXL Hedge Fund Activity: Q2 2022 in Review
150 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Anavex Life Sciences (AVXL) for Q2 2022, worth a combined $249M — down 20% from $310M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new AVXL positions and 14 closed out — a net gain of 13 holders — while 46 added to existing stakes and 33 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $4.46M. The largest seller was State Street, cutting an estimated $10.3M.
- 150 institutional investors held Anavex Life Sciences (AVXL) as of Q2 2022, up from 139 in Q1 2022.
- Funds reported $249M of Anavex Life Sciences stock for Q2 2022, down 20% quarter-over-quarter.
- 27 funds opened new Anavex Life Sciences positions in Q2 2022 and 14 closed out, a net change of +13 holders.
- The largest Anavex Life Sciences buyer in Q2 2022 was Citadel Advisors, an estimated $4.46M added.
- The largest Anavex Life Sciences seller in Q2 2022 was State Street, an estimated $10.3M sold.
Based on aggregated 13F filings for Q2 2022.